The Searle Co Ltd SEARL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 588.22M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 23.52
- Price/Sales
- 1.24
- Dividend Yield (Trailing)
- 1.29%
- Dividend Yield (Forward)
- 1.29%
- Dividend Payment Schedule
- —
- Total Yield
- 1.29%
Company Profile
The Searle Co Ltd is engaged in the manufacturing and sale of pharmaceutical and consumer healthcare products. Its portfolio includes prescription medicines, biopharmaceuticals, nutraceuticals, nutritional products, medical devices, and disposables. Key products include Semavi, Rexeva, Valmera, Injecfer, Dalimab, and Extor. The group serves therapeutic areas including cardiovascular, endocrinology, oncology, neurology, respiratory care, gastroenterology, hepatology, and anti-infectives. The majority of the group's revenue is generated from pharmaceutical sales. Geographically, the group generates the majority of its revenue from Pakistan, with additional sales from Sri Lanka, Myanmar, Cambodia, Afghanistan, Vietnam, Oman, and other countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 3,285
- Website
- https://www.searlecompany.com
Valuation
|
Metric
|
SEARL
|
|---|---|
Price/Earnings (Normalized) | 23.52 |
Price/Book Value | 1.36 |
Price/Sales | 1.24 |
Price/Cash Flow | 12.07 |
Price/Earnings
SEARL
Financial Strength
|
Metric
|
SEARL
|
|---|---|
Quick Ratio | 1.19 |
Current Ratio | 1.77 |
Interest Coverage | 4.74 |
Quick Ratio
SEARL
Profitability
|
Metric
|
SEARL
|
|---|---|
Return on Assets (Normalized) | 3.13% |
Return on Equity (Normalized) | 4.76% |
Return on Invested Capital (Normalized) | 4.99% |
Return on Assets
SEARL
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|tV!j$^?K | LOCK|^TPx | $69B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|>$$&fhs# | LOCK|skKlC | $47B | |||
| Haleon PLC ADR
HLN
| LOCK|gjV$#GW | LOCK|@Y | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|>JYJ<?RW | LOCK|hrr | $33B | |||
| Viatris Inc
VTRS
| LOCK|?@!@Y> | LOCK|%jj | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|vg | LOCK|R< | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|PN>>h$ | LOCK|cH | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|B&tC#b | LOCK|XCD | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|LVCjmX | LOCK|x%fJ# | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|XNw$d!# | LOCK|Wh> | $2B |
United States